Synmosa Biopharma Corporation provided earnings guidance for the year 2022. For the period, the company estimated that this year's annual revenue will increase by 36%, the gross profit rate will be 41.8%, and the net profit after tax will exceed TWD 820 million increase by 172%, EPS estimated at TWD 2.5.